Clinical data showed that the responding rate of ICIs is closely correlated with biomarker expression in tumor specimens, for example, PD-L1 status (Borghaei et al., 2015; Herbst et al., 2016; Reck et al., 2016), tumor mutational burden (TMB) (Galvano et al., 2021), microsatellite instability-high (MSI-H) (Gregg et al., 2019; Zhao et al., 2019), and mismatch repair-deficient (MMR-deficient) (Gregg et al., 2019; Zhao et al., 2019). The gene discussed is CD274; the disease is neoplasm.